Gastroenterology Unit, Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy.
Eur J Clin Invest. 2014;44(3):285-94. doi: 10.1111/eci.12231. Epub 2014 Jan 22.
Urotensin (U)-II receptor (UTR) has been previously reported to be over-expressed in a number of tumours. Whether UTR-related pathway plays a role in colon carcinogenesis is unknown.
We evaluated UTR protein and mRNA expression in human epithelial colon cancer cell lines and in normal colon tissue, adenomatous polyps and colon cancer. U-II protein expression was assessed in cancer cell lines. Moreover, we evaluated the effects of U-II(4-11) (an UTR agonist), antagonists and knockdown of UTR protein expression through a specific shRNA, on proliferation, invasion and motility of human colon cancer cells.
Cancer cell lines expressed U-II protein and UTR protein and mRNA. By immunohistochemistry, UTR was expressed in 5-30% of epithelial cells in 45 normal controls, in 30-48% in 21 adenomatous polyps and in 65-90% in 48 colon adenocarcinomas. UTR mRNA expression was increased by threefold in adenomatous polyps and eightfold in colon cancer, compared with normal colon. U-II(4-11) induced a 20-40% increase in cell growth while the blockade of the receptor with specific antagonists caused growth inhibition of 20-40%. Moreover, the knock down of UTR with a shRNA or the inhibition of UTR with the antagonist urantide induced an approximately 50% inhibition of both motility and invasion.
UTR appears to be involved in the regulation of colon cancer cell invasion and motility. These data suggest that UTR-related pathway may play a role in colon carcinogenesis and that UTR may function as a target for therapeutic intervention in colon cancer.
先前已有报道称,尾加压素(U)-II 受体(UTR)在许多肿瘤中过度表达。UTR 相关途径是否在结肠癌变中起作用尚不清楚。
我们评估了人上皮结肠癌细胞系和正常结肠组织、腺瘤性息肉和结肠癌中 UTR 蛋白和 mRNA 的表达。评估了癌症细胞系中 U-II 蛋白的表达。此外,我们还评估了 U-II(4-11)(UTR 激动剂)、拮抗剂和通过特异性 shRNA 降低 UTR 蛋白表达对人结肠癌细胞增殖、侵袭和迁移的影响。
癌细胞系表达 U-II 蛋白和 UTR 蛋白和 mRNA。通过免疫组织化学染色,在 45 例正常对照中,UTR 在 5-30%的上皮细胞中表达,在 21 例腺瘤性息肉中在 30-48%的上皮细胞中表达,在 48 例结肠腺癌中在 65-90%的上皮细胞中表达。与正常结肠相比,腺瘤性息肉中 UTR mRNA 表达增加了三倍,结肠腺癌中增加了八倍。UTR 激动剂 U-II(4-11)诱导细胞生长增加 20-40%,而特异性拮抗剂阻断受体导致细胞生长抑制 20-40%。此外,shRNA 敲低 UTR 或拮抗剂 urantide 抑制 UTR 可导致运动和侵袭性降低约 50%。
UTR 似乎参与了结肠癌细胞侵袭和迁移的调节。这些数据表明,UTR 相关途径可能在结肠癌变中起作用,UTR 可能作为结肠癌治疗干预的靶点。